Saturday, November 14, 2026

AI systems now execute cryptocurrency payments, influence US military strikes on Iran

MoonPay launched autonomous payment agents on February 24, 2026, while Claude AI helps prioritize US strike targets in Iran. The shift from question-answering chatbots to action-executing agents is accelerating across financial services, military operations, and healthcare in Q1 2026.

From our archive, published before source-traceability. How we work

AI systems now execute cryptocurrency payments, influence US military strikes on Iran
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

MoonPay launched autonomous payment agents on February 24, 2026, enabling AI systems to execute cryptocurrency transactions without human approval. Claude AI is simultaneously helping US forces identify and prioritize strike targets in Iran, MIT Technology Review reported.

The deployment marks a global transition from chatbots that answer questions to agents that take action. "Companies have AI that can answer questions, but not AI that can act," said MoonPay's Murali Swaminathan.

Three agent categories are emerging across international markets: financial agents executing transactions, tactical agents recommending military actions, and workflow agents automating professional services. Rad AI's healthcare system makes scheduling decisions for radiologists without human intervention.

Enterprise adoption requires new infrastructure unavailable in most markets. AI agents need API integrations, permission frameworks limiting action scope, and audit trails tracking autonomous decisions. These differ from text-generating chatbots deployed globally since 2022.

The shift changes development priorities worldwide. Traditional large language models optimize for accuracy and knowledge retrieval. Autonomous agents require decision-making frameworks and safety constraints preventing unintended consequences.

Liability questions remain unresolved across jurisdictions. When AI agents execute payments or influence military strikes, accountability frameworks must determine responsibility for autonomous decisions. Current regulations in the US, EU, and Asia treat AI as advisory tools, not decision-making entities.

Investment is flowing toward agentic platforms. MoonPay Agents targets developers building AI applications interacting with financial systems, creating a category beyond conversational AI tools dominating markets since ChatGPT's 2022 launch.

Q1-Q2 2026 will test global enterprise appetite for autonomous agents versus traditional chatbots. Early adoption in US military operations and international payment systems suggests high-stakes domains are moving fastest, despite greater risks and regulatory uncertainty across borders.


Sources:
1 Yahoo Finance, "Commotion Launches Enterprise AI Operating System Powered by NVIDIA Nemotron™ Open Models to Scale P" (February 23, 2026)
2 Yahoo Finance, "This Nuclear Energy Trend Could Be Bigger Than Investors Think in 2026" (March 21, 2026)
3 Nasdaq, "1 Artificial Intelligence (AI) Stock That Could Be Worth a Fortune by 2030" (March 21, 2026)
4 Yahoo Finance, "History says these 2 overlooked asset classes are the only real shield against 1970s-style stagflati" (March 21, 2026)
5 Yahoo Finance, "Nadella paid $650M to recruit his AI chief. After 2 years he's quietly pushing him aside — these bru" (March 21, 2026)

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com